Clearside captures $7.9 million in new investment

February 4, 2013 at 12:40 pm Leave a comment

Mountain Capital Group and its affiliates and Santen, a wholly owned subsidiary of Japan-based Santen Pharmaceuticals, are funding a $7.9 million investment Clearside Biomedical.  A graduate of GRA VentureLab, Clearside offers a proprietary microinjection system developed at Georgia Tech and is testing a new drug developed at Emory University to treat posterior ocular diseases.

“I cannot imagine a better alliance as we continue to understand the role the suprachoroidal space will play in dosing medicine directly to the site of retinal disease in patients experiencing retinal blindness,” said Dan While, Clearside’s chief executive.

In January 2012, the company closed a $4 million Series A round with investments from the GRA Venture Fund, Hatteras Venture Partners and Kenan Flagler Business School Private Equity Fund.  Read more here>

Entry filed under: Commercialization/VentureLab, News.

Comcast picks Lancope for network visibility, security Duke University to honor Max Cooper

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed